Ipca Laboratories

Mumbai, India Founded: 1949 • Age: 77 yrs Listed
Ipca Laboratories is engaged in pharmaceutical manufacturing and distribution.
Request Access
Report Incorrect Data
Page last updated

About Ipca Laboratories

Ipca Laboratories is a publicly listed company based in Mumbai (India) founded in 1949. Ipca Laboratories is engaged in pharmaceutical manufacturing and distribution. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. The company has 17,422 employees. Ipca Laboratories has completed 2 acquisitions, including Onyx Scientific and Pisgah Labs. Its Indian entity Ipca Laboratories Limited reported revenue of ₹9,838 Cr. Ipca Laboratories offers products and services including APIs, Formulations, and Generics. Its focus areas include Pharmaceuticals and Generic Drugs.

Company details

Ipca Laboratories is involved in the production and distribution of active pharmaceutical ingredients (APIs), formulations, and generic drugs. The company operates in the healthcare sector, focusing on both domestic and international markets. Solutions are provided to enhance affordability and access to healthcare through competitive pricing and backward integration. Emphasis is placed on maintaining a reliable supply chain and cost competitiveness, positioning Ipca as a leading API exporter from India. Corporate social responsibility initiatives are undertaken to support patient health, environmental sustainability, and community development.

  • Headquarters Mumbai, India
  • Employees 17,422
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    •••• ••••
  • Website ipcalabs.com
  • Social LinkedIn
  • Legal Name Ipca Laboratories Ltd
  • Date of Incorporation 19 Oct, 1949
  • Jurisdiction Mumbai, Maharashtra, India
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹48,869 Cr

    IPCALAB · NSE

  • Share Price
    ₹1,927.80

    +0.08% today

  • Revenue
    ₹9,646 Cr

    FY 2025-26 · +7.9% YoY

  • EBITDA
    ₹1,878 Cr

    Margin 19.5%

  • Net Profit
    ₹1,180 Cr

    FY 2025-26 · +38.2% YoY

  • P/E (TTM)
    35.7x

    P/B 6.1x

  • ROE
    15.9%

    ROCE 19.0%

  • Debt / Equity
    0.14

    Interest cover 5.4x

  • Employee Count
    17,422
  • Investments & Acquisitions
    Onyx Scientific

    & 1 more

Products & Services of Ipca Laboratories

Ipca Laboratories offers a comprehensive portfolio of products and services, including APIs, Formulations, and Generics.

APIs
Pharmaceuticals

Active pharmaceutical ingredients are produced for global markets.

Formulations
Pharmaceuticals

Finished pharmaceutical formulations are developed for various regions.

Generics
Pharmaceuticals

Generic drugs are offered to enhance healthcare affordability.

Board of directors of Ipca Laboratories Limited (Ipca Laboratories)

Ipca Laboratories Limited is the primary company behind Ipca Laboratories. The board of Ipca Laboratories Limited currently have 8 directors; the longest-serving is Pranay Premchand Godha, appointed in 2009. 11 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pranay Premchand Godha
DIN 00016525
Managing Director30 Jul 200917 yrs 3 moIpca Laboratories Limited
Ajit Kumar Jain
DIN 00012657
Managing Director21 Aug 200917 yrs 2 moIpca Laboratories Limited
Prashant Godha
DIN 00012759
Director28 Jul 201115 yrs 3 moIpca Laboratories Limited
Premchand Gigalal Godha
DIN 00012691
Whole-time director31 Jan 201214 yrs 9 moIpca Laboratories Limited
Kamal Kishore Seth
DIN 00194986
Director29 Mar 20197 yrs 7 moIpca Laboratories Limited
Narendra Mairpady
DIN 00536905
Director20 Oct 20224 yrsIpca Laboratories Limited
Swati Arvind Patankar
DIN 06594600
Director14 Feb 20242 yrs 8 moIpca Laboratories Limited
Vivek Keshav Shiralkar
DIN 00340316
Director29 May 20242 yrs 5 moIpca Laboratories Limited

People of Ipca Laboratories

44 people are tracked at Ipca Laboratories (22 in leadership, 4 in board & advisors, 18 in team); the tracked headcount is 17,422.

NameRoleGroup
Premchand Godha
Chairman & Managing DirectorLeadership
Ajit Kumar Jain
Joint Managing DirectorLeadership
Ashok Kumar
President, R&D (Chemical)Leadership
Kavita Sehwani
President, GenericsLeadership
Prabodh Dwivedi
Head Of Quality AssuranceLeadership
Rajendra Dadhich
Senior Vice President - Corporate QualityLeadership
Anil Pareek
President, Medical Affairs & Clinical ResearchLeadership
Shailesh Laul
President, Operations (Formulations)Leadership
Goutam Muhuri
President, R&D (Formulations)Leadership
Dr. Janardhana Rao Vascuri
Associate Vice President - Head R&d (api)Leadership
Dr Indranil Purkait
Sr General ManagerLeadership
Srikant Pande
Site Head ( Formulation) General ManagerLeadership
Shashi Kant
Manager, QC Head At IPCA Laboratory Ltd.Leadership
Nitin Chandurkar
Senior Vice President Global Clinical Research And DevelopmentLeadership
Dr. Ghanshyam Maurya
Assistant General Manager API R&dLeadership
Yogendra Singh Bisht Bisht
Assistant General ManagerLeadership
Dr.ashvini Saxena
Vice President R&dLeadership
Harvinder Singh
Associate Vice President - Analytical Development At Ipca Laboratories LimitedLeadership
Krishna Kumar
Deputy General ManagerLeadership
Jyotirmoy Bhowmick
Business Head East AfricaLeadership

24 more people are available in the full profile.

Premium access

Complete people profiles for Ipca Laboratories

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Ipca Laboratories

Ipca Laboratories is a publicly listed company on the NSE with ticker symbol IPCALAB in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: IPCALAB
  • Listed entityIpca Laboratories Limited
  • Exchange sectorPharmaceuticals

Financials of Ipca Laboratories

Exchange-reported figures of Ipca Laboratories Limited, the listed company behind Ipca Laboratories (NSE: IPCALAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹9,646 Cr
+7.9% YoY
EBITDA
₹1,878 Cr
+23.2% YoY
Profit After Tax
₹1,180 Cr
+38.2% YoY
Net Worth
₹8,064 Cr
+16.1% YoY
Total Assets
₹10,431 Cr
+5.9% YoY
Total Debt
₹809 Cr
-40.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Profit before tax1,5731,1318437451,1361,389739
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Balance sheet
Total assets10,4319,8489,2537,4446,4215,0224,176
Net worth8,0646,9486,3325,8425,4924,7023,627
Total debt8091,3631,4381,481807265501
Cash & bank5653442971,853641365181
Net working capital4,0463,5863,4403,8732,6622,1311,676
Cash flow
Cash from operations1,1421,3219458068561,090570
Cash from investing(247)(870)(1,215)(725)(851)(521)(509)
Cash from financing(754)(283)(553)507427(306)(137)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%---
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Profit before tax1,5321,0008227501,0741,380785
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Balance sheet
Total assets8,3437,8567,5517,3656,2965,0284,185
Net worth7,9796,8926,3495,8775,4764,7533,678
Total debt2959061,1521,440776236474
Cash & bank3631651131,706596307152
Net working capital2,4032,1042,1743,6492,5222,0371,615
Cash flow
Cash from operations1,3781,3748317628321,096561
Cash from investing(697)(739)(1,355)(710)(812)(560)(499)
Cash from financing(745)(428)(465)506426(307)(139)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%---
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 31 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,7882,3882,3922,5562,3092,2472,2452,355
Revenue growth (YoY)+20.8%+6.3%+6.6%+8.6%+10.3%---
Other income25.2693.7437.8427.8632.6625.8220.1126.26
EBITDA670438533487416224463441
EBITDA margin+24.0%+18.3%+22.3%+19.0%+18.0%+10.0%+20.6%+18.7%
Depreciation11110710810310010098.46100
Interest11.8820.2017.6219.6118.5121.5116.8122.56
Profit before tax572404446392331128368345
Tax14995.0581.9310896.0962.2290.5999.39
Net profit42330936428423465.78277245
EPS (₹)15.8411.7912.8611.149.192.679.789.05
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue9,6468,9407,7056,2445,8305,4204,619
Revenue growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
Other income19292.8019312666.5762.8467.00
Total expenses7,7697,4166,5575,3154,5173,8723,717
Employee cost2,1601,9841,7081,2881,1771,014921
EBITDA1,8781,5241,1489291,3131,548902
EBITDA margin+19.5%+17.1%+14.9%+14.9%+22.5%+28.6%+19.5%
Depreciation418398357262232209210
Interest79.0987.8414148.1911.2012.2719.77
Profit before tax1,5731,1318437451,1361,389739
Tax381344313253225240135
Net profit1,1808545944548851,134597
Net profit margin+12.2%+9.6%+7.7%+7.3%+15.2%+20.9%+12.9%
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus8,0386,9236,3075,8175,4674,6763,590
Shareholders' funds (net worth)8,0646,9486,3325,8425,4924,7023,627
Minority interest1,4601,4401,39573.3076.9214.5313.63
Secured loans7041,1561,210858555141324
Unsecured loans105206229623253124176
Total debt8091,3631,4381,481807265501
Total liabilities10,4319,8489,2537,4446,4215,0224,176
Assets
Gross block7,6926,9957,0214,3653,7593,2122,986
Net block4,6274,2674,5542,7512,4182,0722,059
Capital work in progress773622343140306235133
Investments844980862626989505310
Inventories2,7312,5602,4711,7431,8581,5951,323
Sundry debtors2,0141,8841,687989911812895
Cash & bank balances5653442971,853641365181
Loans & advances430415522280318272218
Total current assets5,7405,2044,9774,8663,7273,0432,617
Total current liabilities1,6941,6181,5389931,065913942
Net working capital4,0463,5863,4403,8732,6622,1311,676
Total assets10,4319,8489,2537,4446,4215,0224,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash9257561,579991559295371
Net cash from operating activities1,1421,3219458068561,090570
Net cash from investing activities(247)(870)(1,215)(725)(851)(521)(509)
Net cash from financing activities(754)(283)(553)507427(306)(137)
Net change in cash142169(823)588432264(75.53)
Closing cash5653442971,853641365181
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+7.9%+16.0%+23.4%+7.1%+7.6%+17.3%-
EBITDA growth+23.2%+32.8%+23.5%-29.2%-15.2%+71.5%-
PBT growth+39.0%+34.2%+13.1%-34.4%-18.2%+88.0%+35.2%
Net income growth+38.2%+43.8%+30.7%-48.7%-21.9%+90.0%-
Revenue CAGR (3Y)+15.6%+15.3%+12.4%+10.6%+15.9%+18.5%+13.5%
EBITDA CAGR (3Y)+26.4%+5.1%-9.5%+1.0%+23.7%+50.5%+26.2%
Profitability & leverage
Net income margin+12.4%+8.8%+6.9%+7.9%+15.6%+21.2%+13.1%
Return on capital employed+19.0%+17.1%+12.9%+11.6%+20.2%+30.6%+19.5%
Return on net worth+15.9%+13.6%+8.7%+8.7%+17.9%+27.6%+17.9%
Debt / equity0.140.210.240.200.110.090.14
Long-term debt / equity0.050.090.110.100.040.020.04
Interest cover5.427.8017.807.221.040.922.86
Efficiency & per share
Fixed asset turnover1.311.281.351.541.671.751.65
Inventory turnover3.653.553.663.473.383.713.88
Debtors turnover4.955.015.766.576.776.355.90
EPS (₹)44.9829.0821.5718.5834.8589.8747.99
Dividend per share (₹)0.004.004.004.008.008.005.00
Book value per share (₹)317.85273.88249.59230.27216.47370.65286.15
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,1191,8141,8451,9301,7471,6381,6631,811
Revenue growth (YoY)+21.3%+10.7%+11.0%+6.6%+11.6%---
Other income17.4229.8817.8221.9225.0221.4917.4117.00
Total expenses1,5421,4141,3681,4661,3401,5611,2521,409
EBITDA57840147746540777.05411402
EBITDA margin+27.3%+22.1%+25.9%+24.1%+23.3%+4.7%+24.7%+22.2%
Depreciation74.6170.3168.5766.8663.1365.1962.8162.65
Interest5.0410.489.5111.4612.0616.2010.1717.25
Profit before tax51535041740835717.15356339
Tax14287.5611410494.7182.2087.9695.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue7,3376,6786,1665,8155,4385,1394,338
Revenue growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
Other income94.6471.2911111152.9262.2464.69
Total expenses5,5855,4325,0874,9004,1973,6233,420
Employee cost1,6561,4791,3361,1931,102949871
EBITDA1,7521,2461,0809141,2411,517918
EBITDA margin+23.9%+18.7%+17.5%+15.7%+22.8%+29.5%+21.2%
Depreciation269252246229210188179
Interest45.4665.0612346.3410.4111.1318.84
Profit before tax1,5321,0008227501,0741,380785
Tax400349292245214239133
Net profit1,1368206004888531,132642
Net profit margin+15.5%+12.3%+9.7%+8.4%+15.7%+22.0%+14.8%
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital25.3725.3725.3725.3725.3725.3725.27
Reserves & surplus7,9546,8666,3235,8525,4504,7273,640
Shareholders' funds (net worth)7,9796,8926,3495,8775,4764,7533,678
Secured loans235726991858555114298
Unsecured loans60.06180161582222123176
Total debt2959061,1521,440776236474
Total liabilities8,3437,8567,5517,3656,2965,0284,185
Assets
Gross block5,0374,3884,1663,8893,3652,8992,689
Net block2,9692,5372,5242,4792,1531,8691,841
Capital work in progress45949017512329718284.19
Investments2,5362,6932,6541,0571,339868649
Inventories1,7081,5421,6771,6601,7801,5171,267
Sundry debtors1,2721,1661,027926824774839
Cash & bank balances3631651131,706596307152
Loans & advances304255282260306285215
Total current assets3,6473,1283,0994,5523,5052,8842,474
Total current liabilities1,2441,024925903983847859
Net working capital2,4032,1042,1743,6492,5222,0371,615
Total assets8,3437,8567,5517,3656,2965,0284,185
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash7225151,505946500272348
Net cash from operating activities1,3781,3748317628321,096561
Net cash from investing activities(697)(739)(1,355)(710)(812)(560)(499)
Net cash from financing activities(745)(428)(465)506426(307)(139)
Net change in cash(64.08)207(990)559446229(76.37)
Closing cash3631651131,706596307152
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.9%+8.3%+6.1%+6.9%+5.8%+18.5%-
EBITDA growth+40.7%+15.3%+18.1%-26.3%-18.2%+65.2%-
PBT growth+53.3%+21.6%+9.6%-30.1%-22.2%+75.8%+40.8%
Net income growth+38.5%+36.7%+22.9%-42.7%-24.7%+76.5%-
Revenue CAGR (3Y)+8.1%+7.1%+6.3%+10.3%+14.7%+17.2%+11.8%
EBITDA CAGR (3Y)+24.2%+0.1%-10.7%-0.1%+21.3%+50.5%+28.3%
Profitability & leverage
Net income margin+15.4%+9.7%+8.6%+8.7%+15.8%+22.2%+15.0%
Return on capital employed+19.5%+17.2%+14.1%+11.7%+19.2%+30.2%+20.6%
Return on net worth+15.2%+12.4%+9.8%+8.9%+16.8%+27.1%+19.2%
Debt / equity0.080.160.210.200.100.080.13
Long-term debt / equity0.040.080.100.090.040.010.03
Interest cover3.076.5514.716.761.010.842.55
Efficiency & per share
Fixed asset turnover1.561.561.531.601.741.841.71
Inventory turnover4.524.153.703.383.303.693.76
Debtors turnover6.026.096.316.646.806.375.94
EPS (₹)44.6425.6520.9119.9333.9189.9351.64
Dividend per share (₹)6.004.004.004.004.008.005.00
Book value per share (₹)314.52271.64250.24231.66215.84374.67290.11

Investments & Acquisitions by Ipca Laboratories

Ipca Laboratories has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Onyx Scientific and Pisgah Labs.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Pisgah Labs
Contract manufacturing and co-development partnerships are provided.
pisgahlabs.comBrevard, United States1979Jan 2018$9.65M
Onyx Scientific
Custom synthesis and GMP manufacturing services are provided for pharmaceuticals.
onyxipca.comSunderland, United Kingdom2000Aug 2011$7.5M
Premium access

Complete acquisition details for Ipca Laboratories

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Ipca Laboratories

3 dated milestones of Ipca Laboratories across 69 years, from founding to its latest funding, stage changes and deals.

  1. Founded Ipca Laboratories is founded.
  2. Acquisition Acquires Onyx Scientific.
  3. Acquisition Acquires Pisgah Labs.

Web traffic of Ipca Laboratories

Websites that share an audience with Ipca Laboratories (ipcalabs.com).

Similar websites

Websites whose visitors overlap most with Ipca Laboratories. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Ipca Laboratories
ipca.com
100%
20.7K#1,302,903View details
Pharm-Olam
pharm-olam.com
100%
View details
Medpace
medpace.com
96%
240.7K#213,697View details
GVK Davix Technologies
gvkbio.com
90%
View details
Lambda Therapeutic
lambda-cro.com
87%
38.8K#490,207View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 9 similar websites and full traffic analytics for Ipca Laboratories

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ipca Laboratories

Technical analysis: Two Trades for Today: A mid-cap pharma stock for a 5.3% upmove, a capital goods manufacturer for an almost 7% gain - The Economic Times
Economic Times • 1 month ago
Momentum Stocks: PNB Housing Finance, Divis Labs, Ipca Labs, Paytm hit 52-week high
Moneycontrol • 2 months ago
Buy Ipca Laboratories; target of Rs 2060: Motilal Oswal
Moneycontrol • 2 months ago
Ipca Laboratories shares jump 12% to hit record high on strong Q1 show; check revised target prices - BusinessToday
Business Today • 2 months ago
Ipca Laboratories shares gain 5.35% to Rs 1,827
Moneycontrol • 2 months ago
Buy Ipca Laboratories; target of Rs 2000: Prabhudas Lilladher
Moneycontrol • 2 months ago
Buy Ipca Laboratories; target of Rs 1950: Emkay Global Financial
Moneycontrol • 2 months ago
Momentum Stocks: Ipca Labs, Expleo Solution, Armour Security advance amid sheer momentum
Moneycontrol • 2 months ago
IPCALAB: Revenue up 21% and EBITDA margin to 22.88%, with FY27 growth guidance raised to 14%-16%
Quartr • 2 months ago
Ipca Laboratories shares fall over 2%; strong financial performance reported
Moneycontrol • 2 months ago
Premium access

Complete news archive for Ipca Laboratories

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ipca Laboratories

Ipca Laboratories was founded in 1949.

Ipca Laboratories is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Ipca Laboratories has 17,422 employees.

The primary company behind Ipca Laboratories, Ipca Laboratories Limited, reported revenue of ₹9,838 Cr for FY 2026, up 8% year on year.

Ipca Laboratories is involved in the production and distribution of active pharmaceutical ingredients (APIs), formulations, and generic drugs. The company operates in the healthcare sector, focusing on both domestic and international markets. Solutions are provided to enhance affordability and access to healthcare through competitive pricing and backward integration. Emphasis is placed on maintaining a reliable supply chain and cost competitiveness, positioning Ipca as a leading API exporter from India. Corporate social responsibility initiatives are undertaken to support patient health, environmental sustainability, and community development.

Ipca Laboratories offers APIs, Formulations, and Generics.

Yes, Ipca Laboratories is publicly traded on NSE under the ticker symbol IPCALAB.

Ipca Laboratories has made 2 acquisitions, including Onyx Scientific, and Pisgah Labs.

Ipca Laboratories operates through Ipca Laboratories Limited.

The legal entities of Ipca Laboratories currently have 9 directors, including Narendra Mairpady, Ajit Kumar Jain, Kamal Kishore Seth and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available